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Abstract
Aims The mortality in cardiogenic shock (CS) is high. The role of specific mechanical circulatory support (MCS) systems is
unclear. We aimed to compare patients receiving Impella versus ECLS (extracorporal life support) with regard to baseline char-
acteristics, feasibility, and outcomes in CS.
Methods and results This is a retrospective cohort study including CS patients over 18 years with a complete follow-up of
the primary endpoint and available baseline lactate level, receiving haemodynamic support either by Impella 2.5 or ECLS from
two European registries. The decision for device implementation was made at the discretion of the treating physician. The pri-
mary endpoint of this study was all-cause mortality at 30 days. A propensity score for the use of Impella was calculated, and
multivariable logistic regression was used to obtain adjusted odds ratios (aOR).
In total, 149 patients were included, receiving either Impella (n = 73) or ECLS (n = 76) for CS. The feasibility of device implantation
was high (87%) and similar (aOR: 3.14; 95% CI: 0.18–56.50; P = 0.41) with both systems. The rates of vascular injuries (aOR: 0.95;
95% CI: 0.10–3.50; P = 0.56) and bleedings requiring transfusions (aOR: 0.44; 95% CI: 0.09–2.10; P = 0.29) were similar in ECLS
patients and Impella patients. The use of Impella or ECLS was not associatedwith increased odds of mortality (aOR: 4.19; 95% CI:
0.53–33.25; P = 0.17), after correction for propensity score and baseline lactate level. Baseline lactate level was independently
associated with increased odds of 30 day mortality (per mmol/L increase; OR: 1.29; 95% CI: 1.14–1.45; P < 0.001).
Conclusions In CS patients, the adjusted mortality rates of both ECLS and Impella were high and similar. The baseline lactate
level was a potent predictor of mortality and could play a role in patient selection for therapy in future studies. In patients
with profound CS, the type of device is likely to be less important compared with other parameters including non-cardiac
and neurological factors.
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Introduction
Cardiogenic shock (CS) is still associated with a high mortality
rate, especially after cardiac arrest.1,2 CS due to acute myo-
cardial infarction (AMI-CS) and cardiac arrest CS (CA-CS)
constitute the two major causes of the disease.3 Despite ad-
vances in medical management including the administration
of inotropes, vasopressors, and the introduction of dedi-
cated shock teams, mortality remains high. Expectations
are therefore currently put in mechanical circulatory
support (MCS) systems, which may help to improve
haemodynamic condition without vasoconstrictive side
effects that frequently occur after the administration of
catecholamines.1,4–8
In the seventies and eighties, the intra-aortic balloon pump
(IABP) was used in nearly all AMI-CS patients, but recently,
the IABP-SHOCK II trial showed no benefit of IABP as com-
pared with medical treatment.9 The European Society of Car-
diology (ESC) guidelines have downgraded its use to a class III
recommendation for routine use.10 However, new other
promising MCS were developed and successfully tested in
smaller non-randomized registries reporting outcomes of CS
patients.8,11
Extracorporal life support, ECLS, also known as
veno-arterial extracorporeal membrane oxygenation (VA-
ECMO), has become a treatment option in CS patients, espe-
cially after percutaneous insertion has become feasible.12
However, it is still unclear whether ECLS has any beneficial ef-
fect on mortality rate.7
The micro-axial Impella pump provides blood flow from
the left ventricle into the ascending aorta and, thereby, aug-
ments mean arterial pressure and cardiac index. Using the
Impella, flow rates of up to 5.5 L/min depending on the spe-
cific device diameter are feasible. Although the Impella lacks
the oxygenation support in respiratory failure compared with
ECLS, experimental studies reported left ventricular
unloading and improved blood flow to the coronary arteries
in Impella patients, which could be especially beneficial in
CS patients.13 Again, small randomized trials, large observa-
tional studies, and meta-analyses have thus far failed to show
a benefit of Impella versus control.14–19 It is, however, very
likely that patient selection for MCS is very crucial in order
to show any benefit of MCS.
As demonstrated by recent studies, besides clinical judge-
ments and established scores, lactate level is a useful param-
eter for stratifying shock patients. It is directly correlated with
mortality rate and functional outcome in critically ill patients
both with and without MCS.20–23
There are only a few small-sized studies comparing Impella
versus ECLS in CS patients.24–27 We, therefore, aimed to com-
pare Impella versus ECLS patients in a pooled data analysis
from two registries with regard to baseline characteristics,
feasibility, outcomes, and predictors of mortality with partic-
ular focus on baseline lactate concentration.
Methods
Study population and data collection
Patients with CS over 18 years receiving haemodynamic sup-
port either by Impella or ECLS from two European registries,
the Impella-EUROSHOCK registry and the German Lifebridge
registry, were included in this analysis.8,12 Patients were
included from 2005 to 2014. With regard to the
Impella-EUROSHOCK registry, shock criteria were defined at
the discretion of the treating physician based on the SHOCK
(Should We Emergently Revascularize Occluded Coronaries
for Cardiogenic Shock) criteria.28 In order to maximize statis-
tic validity, only patients with a complete follow-up of the pri-
mary endpoint and available baseline lactate level were
included in the study. Importantly, the decision for MCS appli-
cation was made at the discretion of the treating physician.
Both CS patients with AMI-CS and CA-CS were included.
AMI-CS and CA-CS were defined by the treating physician
using a case report form (CRF).
The primary endpoint of the study was all-cause mortality
at 30 days. Left ventricular ejection fraction was obtained
using bedside echo on the day of admission. Ethical approval
was obtained from the ethical committees of the participat-
ing centers.8,12
Device and procedure
Extracorporal life support implantation was performed via
percutaneous femoral access using a 15 to 17 French arte-
rial cannula and 17 to 21 French venous cannulae accord-
ing to the instructions of the manufacturer using
retrograde perfusion cannula. The Impella 2.5 was inserted
through a 13 French femoral arterial sheath and retro-
gradely positioned in the left ventricle. A pigtail-tip aims
to avoid myocardial injury and ensures a stable position
in the LV. The maximum flow provided by the Impella 2.5
device is 2.5 L/min.
Secondary endpoints
The technical feasibility of device implantation was graded
by the implanting physician as ‘easy’, ‘suitable’, or ‘difficult’
using a CRF. In this study, ‘easy’ and ‘suitable’ were consid-
ered ‘feasible’. Renal failure, multi-organ failure, vascular
injury during implantation, and bleeding requiring transfu-
sion were clinically judged and graded using a CRF, and
no formal prespecified protocol was applied for these end-
points which were clinically judged by the treating
physicians.
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Statistical analysis
Statistical analyses were performed using SPSS statistical soft-
ware, version 26.0 (IBM Corp. Released 2019, Armonk, NY,
USA). Baseline patient characteristics, procedural data, com-
plications, and outcomes were analysed for the overall co-
hort. In this analysis, all patients with data on baseline
lactate concentration and 30 day mortality were included.
Missing values were imputed by multiple imputation. In total,
five imputations were calculated. Then, a propensity score on
the use of Impella was calculated using logistic regression
from the covariates sex, age, concomitant diseases (diabetes,
arterial hypertension, hyperlipidaemia, chronic renal insuffi-
ciency, atrial fibrillation, PAD, previous AMI, and previous
CABG), smoking status, mean arterial pressure (MAP), ejec-
tion fraction (EF), BMI, presentation after CPR, shock after
myocardial infarction, use of inotropes and vasopressors,
heart rate, and use of mechanical ventilation for each im-
puted dataset. Results from analyses were pooled for infer-
ence using Rubin’s rules.29 The propensity scores were
applied using the Across approach.30 Categorical variables
are expressed by numbers and percentages. For continuous
variables, data are expressed as median ± interquartile range
(IQR). Differences between independent groups have been
calculated using one-way ANOVA. Logistic regression was
used to evaluate associations with the primary and secondary
endpoints. Odds ratios (OR) and adjusted odds ratios (aOR)
with 95% confidence intervals (CI) were obtained. For a
multivariable logistic regression model, confounders with a
P-value <0.10 in the univariate analysis were included, and
then a backward variable elimination was performed. If not
stated explicitly, aORs refer to propensity score adjustment.
Additionally, multivariable models using propensity score plus
lactate and propensity score plus lactate plus complications
(vascular injury and bleeding needing transfusion) were built.
The elimination criterion was a P-value of more than 0.10.
P-values <0.05 were considered statistically significant.
Results
In total, 149 patients were included in this retrospective anal-
ysis, receiving either Impella (n = 73) or ECLS (n = 76) for CS.
Patients receiving Impella were at a similar age as patients re-
ceiving ECLS (63 ± 19 vs. 63 ± 22; P = 0.18; Table 1). There
were no relevant differences in preexisting diseases between
patients receiving Impella versus ECLS, except for less diabe-
tes in Impella patients (27% vs. 59%; P < 0.001; Table 1).
Patients in the Impella group had in trend higher rates of
low left ventricular ejection fraction (EF< 35%) before device
implantation than patients in the ECLS group (78% vs. 58%),
but haemodynamic parameters such as heart rate and
blood pressure did not differ between the two groups
(Table 2). Baseline lactate levels were higher in ECLS patients
(12.0 ± 12 vs. 4.10 ± 6.30; P < 0.001). ECLS patients
were also more often in the highest lactate level quartile
(>14.7 mmol/L; 39% vs. 10%; P < 0.001).
The rates of previous CPR were higher in ECLS patients
(72% vs. 39%; P < 0.001), whereas the rates of CS due to
acute myocardial infarction were higher in the Impella group
(89% vs. 14%; P < 0.001).
Feasibility, safety, and complications
Feasibility of device implantation was high (‘easy’ or ‘suitable’
in 88%) with both systems and similar between Impella and
ECLS (93% vs. 80%; aOR: 3.14; 95% CI: 56.50; P = 0.41). After
propensity score adjustment, rates of vascular injuries (25%
vs. 12%; aOR: 0.59; 95% CI: 0.10–3.50; P = 0.56) and rates
of bleedings requiring transfusions (64% vs. 27%; aOR: 0.44;
95% CI: 0.09–2.10; P = 0.29) were similar in ECLS and Impella
patients (Table 3).
Outcomes
There was a trend towards higher 30 day mortality in ECLS
patients (83% vs. 70%; OR: 2.09; 95% CI: 0.22–1.04;
P = 0.06; Table 3) in univariable analysis. After correction
for (i) propensity score (aOR: 1.06; 95% CI: 0.17–6.75;
P = 0.95), (ii) propensity score plus lactate concentration at
baseline (aOR: 4.19; 95% CI: 0.53–33.25; P = 0.17), and (iii)
propensity score plus lactate plus procedural feasibility and
vascular injury (aOR: 4.37; 95% CI: 0.51–37.27; P = 0.17),
the use of Impella versus ECLS was not associated with signif-
icantly different odds for 30 day mortality.
Table 1 Baseline characteristics of Impella versus ECLS




(n = 76) P-value
Age (years) 63 (±19) 63 (±22) 0.18
Female 10 (14) 11 (15) 1.00
BMI 27 (±5) 27 (±4) 0.52
Concomitant diseases
Arterial hypertension 45 (62) 50 (66) 0.63
Diabetes mellitus 21 (29) 46 (61) <0.001
Current smoker 22 (30) 24 (32) 0.86
Hyperlipoproteinaemia 25 (34) 23 (30) 0.63
COPD 11 (15) 21 (28) 0.11
Renal insufficiency 18 (25) 11 (14) 0.18
Atrial fibrillation 15 (21) 18 (24) 0.69
Peripheral artery disease 10 (14) 14 (18) 0.41
Previous CABG 5 (7) 11 (14) 0.20
Previous AMI 9 (12) 15 (20) 0.22
Within 90 day 11 (15) 18 (24) 0.20
Continuous variables (age and BMI) are given as median ± IQR.
Categorial variables are given as N (%).
CABG, coronary artery bypass grafting; COPD, chronic obstructive
pulmonary disease.
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In univariable analysis, higher lactate level at baseline was
associated with increased odds of 30 day mortality (per
mmol/L increase; OR 1.24; 95% CI: 1.12–1.37; P < 0.001) at
high predictiveness (AUC: 0.79; 95% CI: 0.71–0.87). Further,
baseline lactate level was associated with 30 day mortality
in a sensitivity analysis assessing only ECLS (OR: 1.34; 95%
CI: 1.12–1.60; P = 0.001) and Impella (OR: 1.21; 95% CI:
1.03–1.42; P = 0.02), as well as patients with previous CPR
(OR: 1.20; 95% CI: 1.05–1.36; P = 0.006) and patients with
acute myocardial infarction (OR: 1.16; 95% CI: 1.02–1.32;
P = 0.03). In a multivariable logistic regression model, base-
line lactate level was independently associated with in-
creased odds of 30 day mortality after correction for
Impella use and propensity score (per mmol/L increase; OR:
1.29; 95% CI: 1.14–1.45; P < 0.001).
In sensitivity analysis (n = 112) excluding patients in the
highest lactate quartile (n = 37), there were no differences
between ECLS and Impella patients (68% vs. 72%; OR: 0.84;
95% CI: 0.37–1.93; P = 0.69) in 30 day mortality. In further
sensitivity analysis evaluating only patients with lactate con-
centration below the median lactate concentration
(≤8.3 mmol/L, i.e. patients in the two lowest baseline lactate
concentrations; n = 76), 30 day mortality was similar (62% vs.
57%; OR: 1.21; 95% CI: 0.44–3.72; P = 0.71) between Impella
and ECLS patients. This finding was consistent in all lactate
quartiles (Q1: 55% vs. 33%; P = 0.34; Q2: 71% vs. 67%;
P = 0.78; Q3: 100% vs. 86%; P = 0.99; Q4: 86% vs. 100%;
P = 0.99; Figure 1).
Discussion
In this study, mortality in CS patients was high, regardless of
the type of MCS applied. Still, the technical feasibility of both
the Impella and ECLS device was reported to be high. The
baseline lactate level was predictive for mortality in all
sub-groups that were assessed. In this retrospective analysis
Table 3 Comparison of the primary and secondary endpoints between Impella versus ECLS (extracorporal life support) patients
Event rate Unadjusted analysis Propensity-adjusted analysis
Impella, n (%) ECLS, n (%) OR 95%CI P-value aOR 95%CI P-value
30 day mortality 51 (70) 63 (83) 0.48 0.22–1.04 0.06 1.06 0.17–6.75 0.95
Procedural endpoints
Vascular injury 9 (12) 19 (25) 0.42 0.17–1.01 0.054 0.59 0.10–3.50 0.56
Procedural feasibility 68 (93) 61 (80) 3.06 1.02–9.16 0.046 3.14 0.18–56.50 0.41
Clinical endpoints (judged by CRF)
Haemolysis 15 (21) 17 (22) 0.91 0.31–2.72 0.86 0.63 0.08–5.23 0.65
Renal failure 25 (34) 29 (38) 0.85 0.42–1.72 0.66 0.52 0.07–3.72 0.49
Bleeding requiring transfusion 20 (27) 49 (64) 0.20 0.10–0.41 <0.001 0.44 0.09–2.10 0.29
Multi-organ failure 28 (38) 25 (33) 1.26 0.60–2.62 0.54 1.62 0.18–14.62 0.64
Reported are unadjusted ORs and propensity-score adjusted aORs with respective 95% CI and P-values.
CRF, case report-form; ECLS, extracorporal life support.
Table 2 Clinical characteristics, haemodynamic parameters, and lactate concentrations prior to MCS (mechanical circulatory support)
implantation
Impella (n = 73) ECLS (n = 76) P-value
Previous CPR 27 (37) 55 (72) <0.001
Acute myocardial infarction 65 (89) 11 (14) <0.001
Medical haemodynamic support
Vasopressor use 62 (85) 64 (84) 0.001
Inotropes use 56 (77) 58 (76) 0.04
Haemodynamic parameters
Mean arterial pressure <65 mmHg 34 (47) 33 (43) 0.82
Heart rate (b.p.m.) 102 (±26) 92 (±48) 0.11
Left ventricular ejection fraction <35% 57 (78) 44 (58) 0.06
Mechanical ventilation 57 (78) 56 (74) 0.61
Lactate (mmol/L)
Baseline concentration 4.10 (±6.30) 12.0 (±12) <0.001
Baseline lactate (quartiles) <0.001
0–3.5 mmol/L 31 (42%) 6 (8%)
>3.5–8.3 mmol/L 24 (33%) 15 (20%)
>8.3–14.7 mmol/L 11 (15%) 25 (33%)
>14.7 mmol/L 7 (10%) 30 (39%)
Continuous variables (heart rate and lactate baseline concentrations) are given as median ± IQR. Categorial variables are given as N (%).
CPR, cardiopulmonary reanimation; ECLS, extracorporal life support.
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of two European registries in patients with CS, treatment
with Impella versus ECLS did not result in a difference in
30 day mortality after correction for lactate values. However,
given the high mortality in this real-world population, the
main finding of this study is that in unselected patients with
profound CS, the type of device is likely to be less important
compared with other parameters including non-cardiac and
neurological factors.
Cardiogenic shock is associated with high mortality. How-
ever, patients included in this analysis had a particularly high
mortality rate. Even after excluding patients with lactate con-
centration in the highest quartile (above 14.7 mmol/L;
n = 112) at baseline, the mortality was 70%. In this regard,
this study cohort differs from previous studies comparing
ECLS versus Impella in CS.24–27
In the recent study of Karami et al. comparing Impella
CP/5.0 (n = 90) versus ECLS in CS patients (n = 38), the mor-
tality was 53% and 49% in the two groups, respectively.24
Similarly, Schiller et al. reported intensive care unit mortality
rates of 35% and 37% for ECLS and Impella patients.26 Also, in
earlier studies, mortality rates around 50% were
reported.25,27 We can only speculate that patients included
in our analysis were sicker and in more profound shock with
subsequent more severe organ hypoperfusion. This notion is
supported by the high baseline lactate concentrations of pa-
tients included in this analysis, with a median lactate of
8.3 mmol/L, possibly due to the high number of patients
needing CPR.
Still, considering the high mortality, lactate was a
useful predictor of mortality in this study cohort. In
patients with baseline lactate levels in the highest quartile
(>14.7 mmol/L; n = 37), mortality was 97% (36/37 patients).
Together with clinical judgement, lactate levels could help
physicians to assess CS patients before any MCS implanta-
tion. Very high lactate levels (e.g. >15 mmol/L) are likely a
surrogate parameter for already established advanced
end-organ hypoperfusion, hypoxaemia, and threatening end
organ failure. In these situations, MCS application might be
considered futile and palliative.
In this regard, the timing of initiation of MCS could be crit-
ical. In a meta-analysis based on observational data, Impella
application before reperfusion therapy decreased mortality.31
In other observational studies, early MCS implantation was
associated with increased survival and reduced infarct size
and was cardioprotective.32,33 Recently, in AMI patients,
Impella application even before reperfusion was reported to
be feasible, but no data on efficacy are available.34 For this
study cohort, no data on timing was available.
Adjusted mortality rates did not differ between ECLS and
Impella patients in this study, which is in accordance with
previous retrospective studies comparing these two MCS
devices.24–27 Further, although this study cohort differs from
other studies with regard to devices (Impella 2.5 versus
Impella CP/5.0) and severity of sickness of the included pa-
tients, the mortality rate remained similar after matching pa-
tients based on lactate and main aetiology of CS. Therefore,
although this study cohort differs significantly from previous
studies with regard to baseline characteristics, it supports
the notion that individual patient selection may be crucial
and the choice of MCS device should be considered only
Figure 1 The patients were split in four groups based on quartiles of initial lactate concentration (Q1: 0–3.5 mmol/L; Q2:>3.5–8.3 mmol/L; Q3: >8.3–
14.7 mmol/L; Q4: >14.7 mmol/L). Mortality in Q4 and Q3 was 97% and 89%, respectively, and in Q1 49% and in Q2 69% (P < 0.05). Mortality was
similar between Impella and ECLS in all sub-groups (Q1: 55% vs. 33%; P = 0.34; Q2: 71% vs. 67%; P = 0.78; Q3: 100% vs. 86%; P = 0.99; Q4: 86%
vs. 100%; P = 0.99).
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secondary.23,35 Anyway, case reports indicate the potential
strengths of MCS in overcoming CS, for instance due to fulmi-
nant myocarditis.36
Theoretically, higher rates of vascular injury in ECLS could
be explained due to the larger cannulae used for ECLS im-
plantation. However, in the propensity score adjusted analy-
sis, there were no differences in the secondary endpoints
between Impella and ECLS. Importantly, feasibility was high
for both MCS devices. Of note, this study included only pa-
tients receiving the Impella 2.5 device, and results with re-
gard to outcomes, but also feasibility and rates of vascular
injuries, could differ in newer devices such as the Impella
CP or Impella 5.0.
Extracorporal life support and Impella, although both are
potentially promising concepts for CS patients, lack definitive
proof for reducing mortality. Meta-analyses of randomized
trials and large observational studies failed to show a survival
benefit for these MCS which are frequently used.7,18 There-
fore, adequately powered trials for both ECLS (EUROSHOCK
(NCT03813134) and ECLS-SHOCK (NCT02544594) and
(NCT03637205)]; and ANCHOR (NCT04184635) and Impella
(DanGer shock trial) are ongoing and eagerly awaited. The
DanGer shock trial will combine selective patient inclusion
criteria excluding comatose patients, with a newer and po-
tent MCS device, the Impella CP.37
Ultimately, however, the data situation regarding the use
of MCS per se remains inclusive. There is no randomized
evidence of superiority over conservative treatment for ei-
ther ECLS or Impella. So, while our study tries to evaluate
the advantages and disadvantages of ECLS versus
Impella, randomized evidence of MCS versus conservative
treatment is certainly the most pressing scientific challenge.
It may be possible that precise patient selection increases
the effectiveness of MCS, but this is by no means a trivial
task but a huge scientific and especially clinical
challenge. The structured collection and interpretation of
lactate in a clinical context could help in patient selection,
especially if this biomarker is integrated with other
information.
Another therapy option for patients in CS due to severe
heart failure is the implantation of a permanent ventricular
assist device (VAD). Due to the invasiveness of the
operation, VADs are more frequently applied for patients
in more stable clinical conditions, for example, as bridge-
to-transplantation.38 There is also a lack of randomized
evidence for the use of VAD in CS.
Both Impella and ECLS are theoretically favourable in dis-
tinct situations. Impella implantation necessitates smaller ac-
cess site cannulae/sheaths, which could help to avoid
vascular injuries. Further, Impella reduces left ventricular
pressure and could be more cardioprotective, especially if ap-
plied early.31,32,34 Theoretically, Impella might, therefore, be
considered advantageous over ECLS in patients with AMI
and CS.
On the other hand, ECLS could improve outcomes in pa-
tients with respiratory or biventricular failure.23 Furthermore,
combining ECLS with venting strategies may also reduce the
drawbacks of the afterload increase with ECLS.39 However,
given the scarce evidence, these considerations remain spec-
ulative. The new CS classification of the Society for Cardiovas-
cular Angiography and Intervention (SCAI) and clinical
judgement, including early neurological evaluation and lac-
tate levels, could help to select patients who would poten-
tially benefit from MCS.40
Of note, recently, Impella application was even associated
with adverse outcome in a large recent retrospective
analysis.41 Also, even the Impella 5.0, which is theoretically
more potent in increasing cardiac output compared with
Impella 2.5 and Impella CP, failed to improve haemo-
dynamics.42 Therefore, the whole concept of MCS is chal-
lenged, and randomized studies comparing both Impella
and ECLS versus medical treatment are warranted.
Limitations
This study has several limitations, which need to be acknowl-
edged. First, this is a retrospective study comparing patients
receiving distinct devices at the treating physicians’ discre-
tion. Given local policies, individual preferences, and experi-
ence, one of the devices might be practically unavailable for
specific patients, which could reduce the comparability of
the patients investigated here. Second, detailed data on
post-cardiac arrest care were lacking due to the retrospective
nature of the study. Third, only patients on Impella 2.5 were
included in this analysis, and using more potent Impella de-
vices could lead to distinct outcomes. Fourth, no data on
the functional and neurological outcomes of the survivors is
available. Fifth, the timing of MCS implantation was left at
the respective treating physicians’ decision, and no further
information about timing is available for this study cohort.
Sixth, the patients in this retrospective analysis had high mor-
tality, even in the setting of CS, which exposes this analysis
theoretically to selection bias. However, this analysis provides
real-world data on outcomes of CS patients with MCS. Fur-
ther, the high mortality could dilute any beneficial effect on
the outcome of any of the two MCS. Seventh, although all pa-
tients were treated according to guidelines, and all patients
with AMI-CS underwent revascularization, data on revascular-
ization success are lacking. Eighth, we imputed missing data
and, therefore, refrained from propensity score matching as
the best way to match data from multiple imputation; this
is a subject to discussion.30 Also, propensity scores were
calculated for each imputed dataset on relevant baseline
variables. However, relevant confounders could have been
missed, and propensity adjustment can never replace
randomization. Still, our data could help thesis generation.
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Ninth, the specific characteristics of CA in CA-CS patients are
unknown—although centres were asked to include CS pa-
tients, ‘borderline’ patients with refractory CS after CA could
influence the outcomes of ECLS patients. Tenth, the reason
for CS in the Impella group was AMI in 89%, whereas that oc-
curred in only 14% in the ECLS group. The cause of CA as well
as the exact criteria, defining CS in the German Lifebridge reg-
istry, remain unknown, thus limiting the validity of the com-
parison. Eleventh, some of the obtained CIs were wide, and
the study could be underpowered to detect some subtle
differences between ECLS and Impella. Twelfth, due to the
retrospective character of the study, missing baseline lactate
levels led to the exclusion of patients and, therefore, an
incomplete follow-up, what could cause a bias and limit the
validity of the analyses.
However, we think that the study adds insight to available
knowledge, supporting the notion that the choice of a partic-
ular MCS is less important than patients selection.
Still, we think that this analysis of severely sick CS patients
adds a new perspective to the available literature comparing
Impella versus ECLS in CS. But most importantly, it confirms
the similar outcomes of Impella versus ECLS seen in previous
studies in an unselected patient cohort and, therefore, sup-
ports the call for randomized data in highly selected patients
to evaluate the effects of MCS in CS.
Conclusion
In CS patients, the adjusted mortality rates of both ECLS and
Impella were high and similar. The baseline lactate level was a
potent predictor of mortality and could play a role in patient
selection for future studies. In patients with profound CS, the
type of device is likely to be less important compared with
other parameters including non-cardiac and neurological
factors.
Conflict of interest
The authors have nothing to declare.
Funding
No specific funding was received for this study.
References
1. Mebazaa A, Combes A, van Diepen S,
Hollinger A, Katz JN, Landoni G, Hajjar
LA, Lassus J, Lebreton G, Montalescot
G, Park JJ. Management of cardiogenic
shock complicating myocardial infarc-
tion. Intensive Care Med 2018.
2. Feistritzer HJ, Desch S, de Waha S, Jobs
A, Zeymer U, Thiele H. German contri-
bution to development and innovations
in the management of acute myocardial
infarction and cardiogenic shock. Clin
Res Cardiol 2018; 107: 74–80.
3. Mebazaa A, Tolppanen H, Mueller C,
Lassus J, DiSomma S, Baksyte G,
Cecconi M, Choi DJ, Cohen Solal A,
Christ M, Masip J, Arrigo M, Nouira S,
Ojji D, Peacock F, Richards M, Sato N,
Sliwa K, Spinar J, Thiele H, Yilmaz MB,
Januzzi J. Acute heart failure and car-
diogenic shock: a multidisciplinary prac-
tical guidance. Intensive Care Med 2016;
42: 147–163.
4. van Diepen S, Katz JN, Albert NM,
Henry TD, Jacobs AK, Kapur NK, Kilic
A, Menon V, Ohman EM, Sweitzer NK,
Thiele H, Washam JB, Cohen MG, Amer-
ican Heart Association Council on Clini-
cal Cardiology; Council on
Cardiovascular and Stroke Nursing;
Council on Quality of Care and Out-
comes Research; and Mission: Lifeline.
Contemporary management of cardio-
genic shock: a scientific statement from
the American Heart Association. Circula-
tion 2017; 136: e232–e268.
5. Werdan K, Gielen S, Ebelt H, Hochman
JS. Mechanical circulatory support in
cardiogenic shock. Eur Heart J 2014;
35: 156–167.
6. Sayer GT, Baker JN, Parks KA. Heart res-
cue: the role of mechanical circulatory
support in the management of severe re-
fractory cardiogenic shock. Curr Opin
Crit Care 2012; 18: 409–416.
7. Ouweneel DM, Schotborgh JV, Limpens
J, Sjauw KD, Engström AE, Lagrand
WK, Cherpanath TGV, Driessen
AHG, de Mol BAJM, Henriques JPS.
Extracorporeal life support during car-
diac arrest and cardiogenic shock: a
systematic review and meta-analysis.
Intensive Care Med 2016; 42:
1922–1934.
8. Lauten A, Engström AE, Jung C, Empen
K, Erne P, Cook S, Windecker S,
Bergmann MW, Klingenberg R,
Lüscher TF, Haude M. Percutaneous
left-ventricular support with the
Impella-2.5-assist device in acute cardio-
genic shock: results of the Impella-
EUROSHOCK-registry. Circ Heart Fail
2013; 6: 23–30.
9. Thiele H, Zeymer U, Neumann FJ,
Ferenc M, Olbrich HG, Hausleiter J, de
Waha A, Richardt G, Hennersdorf M,
Empen K, Fuernau G, Desch S, Eitel I,
Hambrecht R, Lauer B, Böhm M, Ebelt
H, Schneider S, Werdan K, Schuler G.
Intra-aortic balloon counterpulsation in
acute myocardial infarction complicated
by cardiogenic shock (IABP-SHOCK II):
final 12 month results of a randomised,
open-label trial. Lancet 2013; 382:
1638–1645.
10. Backhaus T, Fach A, Schmucker J, Fiehn
E, Garstka D, Stehmeier J, Hambrecht R,
Wienbergen H. Management and predic-
tors of outcome in unselected patients
with cardiogenic shock complicating
acute ST-segment elevation myocardial
infarction: results from the Bremen
STEMI Registry. Clin Res Cardiol 2018;
107: 371–379.
11. Schiller P, Hellgren L, Vikholm P. Sur-
vival after refractory cardiogenic shock
is comparable in patients with Impella
and veno-arterial extracorporeal mem-
brane oxygenation when adjusted for
SAVE score. Eur Heart J Acute Cardiovasc
Care 2018 2048872618799745.
12. Masyuk M, Abel P, Hug M, Wernly B,
Haneya A, Sack S, Sideris K, Langwieser
N, Graf T, Fuernau G, Franz M,
Impella versus ECLS in cardiogenic shock 7
ESC Heart Failure (2021)
DOI: 10.1002/ehf2.13200
Westenfeld R, Kelm M, Felix SB, Jung C.
Real-world clinical experience with the
percutaneous extracorporeal life sup-
port system: results from the German
Lifebridge((R)) Registry. Clin Res
Cardiol 2020; 109: 46–53.
13. Remmelink M, Sjauw KD, Henriques JP,
de Winter RJ, Koch KT, van der Schaaf
RJ, Vis MM, Tijssen JG, Piek JJ, Baan J
Jr. Effects of left ventricular unloading
by Impella recover LP2.5 on coronary
hemodynamics. Catheter Cardiovasc
Interv 2007; 70: 532–537.
14. Seyfarth M, Sibbing D, Bauer I, Fröhlich
G, Bott-Flügel L, Byrne R, Dirschinger J,
Kastrati A, Schömig A. A randomized
clinical trial to evaluate the safety and
efficacy of a percutaneous left ventricu-
lar assist device versus intra-aortic bal-
loon pumping for treatment of
cardiogenic shock caused by myocardial
infarction. J Am Coll Cardiol 2008; 52:
1584–1588.
15. Ouweneel DM, Eriksen E, Sjauw KD, van
Dongen IM, Hirsch A, Packer EJS, Vis
MM, Wykrzykowska JJ, Koch KT, Baan
J, de Winter RJ, Piek JJ, Lagrand WK,
de Mol BAJM, Tijssen JGP, Henriques
JPS. Percutaneous mechanical circula-
tory support versus intra-aortic balloon
pump in cardiogenic shock after acute
myocardial infarction. J Am Coll Cardiol
2017; 69: 278–287.
16. Karatolios K, Chatzis G, Markus B,
Luesebrink U, Ahrens H, Dersch W, Betz
S, Ploeger B, Boesl E, O’Neill W, Kill C,
Schieffer B. Impella support compared
to medical treatment for post-cardiac ar-
rest shock after out of hospital cardiac
arrest. Resuscitation 2018; 126:
104–110.
17. Alushi B, Douedari A, Froehlig G, Knie
W, Wurster TH, Leistner DM, Staehli
BE, Mochmann HC, Pieske B,
Landmesser U, Krackhardt F, Skurk C.
Impella versus IABP in acute myocar-
dial infarction complicated by cardio-
genic shock. Open Heart 2019; 6:
e000987.
18. Schrage B, Ibrahim K, Loehn T, Werner
N, Sinning JM, Pappalardo F, Pieri M,
Skurk C, Lauten A, Landmesser U,
Westenfeld R, Horn P, Pauschinger M,
Eckner D, Twerenbold R, Nordbeck P,
Salinger T, Abel P, Empen K, Busch
MC, Felix SB, Sieweke JT, Møller JE,
Pareek N, Hill J, MacCarthy P,
Bergmann MW, Henriques JPS,
Möbius-Winkler S, Schulze PC, Ouarrak
T, Zeymer U, Schneider S, Blankenberg
S, Thiele H, Schäfer A, Westermann D.
Impella support for acute myocardial
infarction complicated by cardiogenic
shock. Circulation 2019; 139:
1249–1258.
19. Wernly B, Seelmaier C, Leistner D, Stähli
BE, Pretsch I, Lichtenauer M, Jung C,
Hoppe UC, Landmesser U, Thiele H,
Lauten A. Mechanical circulatory sup-
port with Impella versus intra-aortic bal-
loon pump or medical treatment in
cardiogenic shock—a critical appraisal
of current data. Clin Res Cardiol 2019;
108: 1249–1257.
20. Masyuk M, Wernly B, Lichtenauer M,
Franz M, Kabisch B, Muessig JM,
Zimmermann G, Lauten A, Schulze PC,
Hoppe UC, Kelm M, Bakker J, Jung C.
Prognostic relevance of serum lactate ki-
netics in critically ill patients. Intensive
Care Med 2019; 45: 55–61.
21. Schmidt M, Burrell A, Roberts L, Bailey
M, Sheldrake J, Rycus PT, Hodgson C,
Scheinkestel C, Cooper DJ, Thiagarajan
RR, Brodie D, Pellegrino V, Pilcher D.
Predicting survival after ECMO for re-
fractory cardiogenic shock: the survival
after veno-arterial-ECMO (SAVE)-score.
Eur Heart J 2015; 36: 2246–2256.
22. Muller G, Flecher E, Lebreton G, Luyt
CE, Trouillet JL, Bréchot N, Schmidt M,
Mastroianni C, Chastre J, Leprince P,
Anselmi A, Combes A. The ENCOURAGE
mortality risk score and analysis of
long-term outcomes after VA-ECMO for
acute myocardial infarction with cardio-
genic shock. Intensive Care Med 2016;
42: 370–378.
23. Health care systems in the European
Union countries.
24. Karami M, den Uil CA, Ouweneel DM,
Scholte NT, Engström AE, Akin S,
Lagrand WK, Vlaar AP, Jewbali LS,
Henriques JP. Mechanical circulatory
support in cardiogenic shock from
acute myocardial infarction: Impella
CP/5.0 versus ECMO. Eur Heart J
Acute Cardiovasc. Care 2019 2048872
619865891.
25. Chamogeorgakis T, Rafael A, Shafii AE,
Nagpal D, Pokersnik JA, Gonzalez-
Stawinski GV. Which is better: a minia-
turized percutaneous ventricular assist
device or extracorporeal membrane oxy-
genation for patients with cardiogenic
shock? ASAIO J 2013; 59: 607–611.
26. Schiller P, Hellgren L, Vikholm P. Sur-
vival after refractory cardiogenic shock
is comparable in patients with Impella
and veno-arterial extracorporeal mem-
brane oxygenation when adjusted for
SAVE score. Eur Heart J Acute Cardiovasc
Care 2019; 8: 329–337.
27. Lamarche Y, Cheung A, Ignaszewski A,
Higgins J, Kaan A, Griesdale DEG, Moss
R. Comparative outcomes in cardiogenic
shock patients managed with Impella
microaxial pump or extracorporeal life
support. J Thorac Cardiovasc Surg 2011;
142: 60–65.
28. Hochman JS, Sleeper LA, Webb JG,
Sanborn TA, White HD, Talley JD, Buller
CE, Jacobs AK, Slater JN, Col J,
McKinlay SM, Picard MH, Menegus
MA, Boland J, Dzavik V, Thompson CR,
Wong SC, Steingart R, Forman R,
Aylward PE, Godfrey E, Desvigne-
Nickens P, LeJemtel TH. Early revascu-
larization in acute myocardial infarction
complicated by cardiogenic shock.
SHOCK Investigators. Should we
emergently revascularize occluded coro-
naries for cardiogenic shock. N Engl J
Med 1999; 341: 625–634.
29. Leyrat C, Seaman SR, White IR, Douglas
I, Smeeth L, Kim J, Resche-Rigon M,
Carpenter JR, Williamson EJ. Propensity
score analysis with partially observed
covariates: how should multiple imputa-
tion be used? Stat Methods Med Res
2019; 28: 3–19.
30. Granger E, Sergeant JC, Lunt M.
Avoiding pitfalls when combining multi-
ple imputation and propensity scores.
Stat Med 2019; 38: 5120–5132.
31. Flaherty MP, Khan AR, O’Neill WW.
Early initiation of impella in acute
myocardial infarction complicated by
cardiogenic shock improves survival: a
meta-analysis. JACC Cardiovasc Interv
2017; 10: 1805–1806.
32. Loehn T, O’Neill WW, Lange B, Pfluecke
C, Schweigler T, Mierke J, Waessnig N,
Mahlmann A, Youssef A, Speiser U,
Strasser RH. Long term survival after
early unloading with Impella CP((R))
in acute myocardial infarction compli-
cated by cardiogenic shock. Eur Heart J
Acute Cardiovasc Care 2018
2048872618815063.
33. Esposito ML, Zhang Y, Qiao X, Reyelt L,
Paruchuri V, Schnitzler GR, Morine KJ,
Annamalai SK, Bogins C, Natov PS,
Pedicini R, Breton C, Mullin A, Mackey
EE, Patel A, Rowin E, Jaffe IZ, Karas
RH, Kapur NK. Left ventricular
unloading before reperfusion promotes
functional recovery after acute myocar-
dial infarction. J Am Coll Cardiol 2018;
72: 501–514.
34. Kapur NK, Alkhouli MA, DeMartini TJ,
Faraz H, George ZH, Goodwin MJ,
Hernandez-Montfort JA, Iyer VS,
Josephy N, Kalra S, Kaki A. Unloading
the left ventricle before reperfusion in
patients with anterior ST-segment-
elevation myocardial infarction. Circula-
tion 2019; 139: 337–346.
35. Thiele H, Ohman EM, de Waha-Thiele S,
Zeymer U, Desch S. Management of car-
diogenic shock complicating myocardial
infarction: an update 2019. Eur Heart J
2019; 40: 2671–2683.
36. Fox H, Farr M, Horstkotte D, Flottmann
C. Fulminant myocarditis managed by
extracorporeal life support (Impella(R)
CP): a rare case. Case Rep Cardiol 2017;
2017: 9231959.
37. Udesen NJ, Møller JE, Lindholm MG,
Eiskjær H, Schäfer A, Werner N,
Holmvang L, Terkelsen CJ, Jensen LO,
Junker A, Schmidt H. Rationale and de-
sign of DanGer shock: Danish-German
cardiogenic shock trial. Am Heart J
2019; 214: 60–68.
38. Gummert JF, Haverich A, Schmitto JD,
Potapov E, Schramm R, Falk V. Perma-
nent implantable cardiac support sys-
tems. Dtsch Arztebl Int 2019; 116:
843–848.
39. Russo JJ, Aleksova N, Pitcher I, Couture
E, Parlow S, Faraz M, Visintini S, Simard
T, di Santo P, Mathew R, So DY, Takeda
K, Garan AR, Karmpaliotis D, Takayama
H, Kirtane AJ, Hibbert B. Left ventricu-
lar unloading during extracorporeal
8 B. Wernly et al.
ESC Heart Failure (2021)
DOI: 10.1002/ehf2.13200
membrane oxygenation in patients with
cardiogenic shock. J Am Coll Cardiol
2019; 73: 654–662.
40. Baran DA, Grines CL, Bailey S, Burkhoff
D, Hall SA, Henry TD, Hollenberg SM,
Kapur NK, O’Neill W, Ornato JP, Stelling
K, Thiele H, van Diepen S, Naidu SS.
SCAI clinical expert consensus state-
ment on the classification of cardiogenic
shock: this document was endorsed by
the American College of Cardiology
(ACC), the American Heart Association
(AHA), the Society of Critical Care
Medicine (SCCM), and the Society of
Thoracic Surgeons (STS) in April 2019.
Catheter Cardiovasc Interv 2019; 94:
29–37.
41. Dhruva SS, Ross JS, Mortazavi BJ,
Hurley NC, Krumholz HM, Curtis JP,
Berkowitz A, Masoudi FA, Messenger
JC, Parzynski CS, Ngufor C, Girotra S,
Amin AP, Shah ND, Desai NR. Associa-
tion of use of an intravascular microaxial
left ventricular assist device vs
intra-aortic balloon pump with
in-hospital mortality and major bleeding
among patients with acute myocardial
infarction complicated by cardiogenic
shock. JAMA 2020; 323: 734–745.
42. Bochaton T, Huot L, Elbaz M, Delmas C,
Aissaoui N, Farhat F, Mewton N,
Bonnefoy E, IMPELLA-STIC investiga-
tors. Mechanical circulatory support
with the Impella(R) LP5.0 pump and
an intra-aortic balloon pump for cardio-
genic shock in acute myocardial infarc-
tion: the IMPELLA-STIC randomized
study. Arch Cardiovasc Dis 2020; 113:
237–243.
Impella versus ECLS in cardiogenic shock 9
ESC Heart Failure (2021)
DOI: 10.1002/ehf2.13200
